Randomized phase III trial to compare progression-free survival in patients with metastatic colorectal cancer receiving irinotecan in combination with capecitabine or fluorouracil/leucovorin and bevacizumab (XELIRI-bevacizumab vs FOLFIRI-bevacizumab) as first-line treatment. A study of the Hellenic Cooperative Oncology Group (HeCOG)

Trial Profile

Randomized phase III trial to compare progression-free survival in patients with metastatic colorectal cancer receiving irinotecan in combination with capecitabine or fluorouracil/leucovorin and bevacizumab (XELIRI-bevacizumab vs FOLFIRI-bevacizumab) as first-line treatment. A study of the Hellenic Cooperative Oncology Group (HeCOG)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 22 Nov 2012 Status changed from active, no longer recruiting to completed, based on final results published in BMC Cancer.
    • 29 Oct 2012 Primary endpoint 'Progression-free-survival-rate' has not been met, based on final results published in BMC Cancer.
    • 29 Jun 2012 Final results published in the BMC Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top